

Cover Story
Under ordinary circumstances, business arrangements built around the 340B drug discount program remain shrouded in secrecy.
In Brief
Clinical Roundup


Drugs & Targets
Trending Stories
- ACOG says it will no longer accept federal funding
- Gardiner Harris, acclaimed health care and pharma journalist, on his New York Times bestselling book
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - ANCHOR trial shows that treatment of anal high-grade squamous intraepithelial lesions prevents anal cancer in people with HIV
- “If I’m not dying, I better go live.” Christy Erickson’s cancer diagnosis led to life as a motorcyclist and strongman competitor